EGFR and ovarian carcinoma: Even more importantly, functional analysis could better inform whether changes in BAVT expression could help in the selection of targeted therapies, like: JAK inhibitors to target the JAK1/STAT3 signaling pathway [53], or mTOR inhibitors [54], PARP inhibitors to target HGF-mediated activation in ovarian cancer [57] or PTEN-mutated cells in endometrial cancer [55], and double TKIs therapy to counteract EGFR TKI resistance in endometrial cancer [59].